ArticleScientific reports2025
The prognostic effect and mechanism of erysipelas in cancer-associated lymphedema.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From stasis to systematics: deciphering the pathophysiology of secondary lymphedema through omics.Frontiers in immunology · 2026Review
- Machine learning-based model to predict liposuction outcomes in unilateral breast cancer-related lymphedema.Frontiers in oncology · 2026Article
- Do not mistake symptomatic improvement for disease modification: therapeutic endpoints in secondary lower-extremity lymphedema require inflammation-fibrosis anchoring.Frontiers in immunology · 2026Review
- Primary and Recurrent Erysipelas-Epidemiological Patterns in a Single-Centre Retrospective Analysis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lymphedema is a chronic condition that can follow cancer treatment, and liposuction has been shown to be an effective approach for reducing limb volume in advanced cases. However, recurrence rates vary widely, with prior erysipelas identified as a potentially significant factor influencing prognosis. This study aimed to identify key risk factors for recurrence following liposuction in patients with cancer-associated secondary lymphedema, develop a predictive nomogram model, and investigate the molecular mechanisms by which previous erysipelas may affect recurrence. In a retrospective analysis of 1,016 patients, multivariate logistic regression and propensity score matching identified four independent risk factors, namely, prior erysipelas, hyperlipidemia, severe distal limb edema, and older age, with erysipelas showing the strongest association with poor outcomes (OR 3.98; 95% CI: 2.81-5.69). A validated nomogram demonstrated high predictive accuracy (C-index 0.757, Brier score 0.176) and net clinical benefit in estimating recurrence risk. The nomogram supports personalized treatment strategies, potentially improving patient outcomes. Transcriptome sequencing further revealed that previous erysipelas exacerbates lymphedema through inflammation, tissue remodeling, and metabolic dysregulation, suggesting potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.